SPT Labtech Strengthens Automation Services with BioMicroLab Acquisition
The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.
SPT Labtech, a company that designs and develops automated instrumentation and consumables for life science applications, has expanded its sample management capabilities for the life sciences industry with the recent acquisition of BioMicroLab, a US-based robotics automation provider for life science laboratories. SPT Labtech made the acquisition in February 2021.
BioMicroLab designs and manufactures laboratory automation equipment for biotechnology and scientific research, and its offerings include an extensive range of sample handling and tracking solutions, which complements SPT Labtech's capabilities in modular, automated sample storage systems as well as expands SPT Labtech's product portfolio in the sample management market, SPT Labtech said in a Feb. 15, 2021 press release.
"Over the last 25 years, BioMicroLab has established a well-deserved reputation as a dependable partner for intuitive and reliable benchtop automation. This important investment delivers significant benefits to customers by creating a powerful end-to-end solution to streamline sample management workflows. We are delighted to welcome BioMicroLab to SPT Labtech," said Patrick Bennett, group CEO at SPT Labtech, in the press release.
"SPT Labtech has an impressive track record of harnessing innovation to overcome tough research challenges and deep expertise across a range of life sciences applications. We are confident that customers will benefit from our combined capabilities and look forward to continuing to enable their research success as part of the SPT Labtech team," added David Miller, president of BioMicroLab, in the press release.
Source: SPT Labtech
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
